Xabier Gutiérrez López de Ocáriz

Xabier Gutiérrez López de Ocáriz

Auto-generated profile, based on publicly available information

Xabier Gutiérrez López de Ocáriz

Hospital Universitario Araba, VITORIA-GASTEIZ, AL, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2020 in International Journal of Laboratory Hematology
Verified
Journal Article
Open access
PDF file
XOXabier Gutiérrez López de Ocáriz
Xabier Gutiérrez López de Ocáriz
NQNerea Castro Quismondo
Nerea Castro Quismondo
EGElena Vera Guerrero
Elena Vera Guerrero
MRMario Rodríguez Rodríguez
Mario Rodríguez Rodríguez
RDRosa Ayala Díaz
Rosa Ayala Díaz
JLJoaquín Martínez López
Joaquín Martínez López
Click on the article title to read more.

1 August 2020 in Medicina Clinica
Verified
Journal Article
Closed access
XOXabier Gutiérrez López de Ocáriz
Xabier Gutiérrez López de Ocáriz
NQNerea Castro Quismondo
Nerea Castro Quismondo
MRMario Rodríguez Rodríguez
Mario Rodríguez Rodríguez

9 July 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
XOXabier Gutiérrez López De Ocáriz
Xabier Gutiérrez López De Ocáriz
EPErnesto Pérez Persona
Ernesto Pérez Persona
LCLaura Salcedo Cuesta
Laura Salcedo Cuesta
ECEusebio Martín Chacón
Eusebio Martín Chacón
MAMaialen Sirvent Auzmendi
Maialen Sirvent Auzmendi
IUIanire Etxeguren Urkixo
Ianire Etxeguren Urkixo
Background: Isatuximab, an anti-CD38 monoclonal antibody, is a cornerstone therapy for multiple myeloma (MM). Standard intravenous infusion requires a minimum of 75 minutes per dose, representing a significant burden on patients and day-hospital resources. A rapid 30-minute infusion protocol has shown promise in early clinical trials, but large real-world datasets remain scarce. Methods: We conducted a descriptive, retrospective, multicenter study across 9 Spanish hospitals, including patients with confirmed MM who had received at least one rapid (30-minute) intravenous isatuximab infusion. Demographic, clinical, treatment, and safety data were collected. Infusion-related reactions (IRRs) were graded per CTCAE v5.0. Data cut-off: 1 May 2026. Results: A total of 103 patients were included (median age 66 years; 54.4% female). A total of 1,344 rapid 30-minute infusions were administered. Only 1 IRR was recorded: per-patient rate 0.97% (95% CI: 0.17%–5.30%), per-infusion rate 0.074% (95% CI: 0.013%–0.420%). Notably, 22 patients (21.4%) had experienced IRRs at standard rate; 21 of these (95.5%) completed the rapid protocol without reverting to standard rate. No patient permanently discontinued isatuximab due to an IRR. No treatment failure was attributable to the infusion rate change during the observation period. The protocol generated an estimated 1,008 hours of cumulative day-hospital chair time savings. Conclusion: Rapid 30-minute intravenous isatuximab demonstrates an excellent real-world safety profile, including in patients with prior IRRs, and generates clinically meaningful resource savings. To our knowledge, this is the largest published real-world cohort to date. These findings support its use as a feasible implementation strategy while prospective comparative studies remain warranted.

16 October 2026 in Blood Advances
Verified
Journal Article
Closed access
Fernando Martin-MoroFernando Martin-Moro
Fernando Martin-Moro
AMAna Muntañola
Ana Muntañola
XGXabier Gutiérrez
Xabier Gutiérrez
MVMaría Sofía Vázquez
María Sofía Vázquez
LMLucía Morais
Lucía Morais
ASAntonio Salar
Antonio Salar
There is no established standard treatment of relapsed/refractory (R/R) marginal zone lymphoma (MZL). Zanubrutinib was approved in this setting based on the phase 2 MAGNOLIA trial. We retrospectively evaluated the characteristics and outcomes of 118 real-world patients in Spain with R/R MZL treated with zanubrutinib after at least 1 previous anti-CD20–based regimen. The median age at zanubrutinib initiation was 75 years, and 56% were female. MZL subtypes included splenic (55.3%), mucosa-associated lymphoid tissue (18.9%), nodal (19.8%), and nonclassifiable (6%). The median number of previous lines of therapy (LoT) was 1.5 (range, 1-7); 26% of patients had MZL refractory to the immediately preceding line, and 59% experienced progression of disease within 24 months (POD24) to frontline therapy. In total, 31 patients (26.3%) would not have met MAGNOLIA trial eligibility criteria, 68% had cardiovascular comorbidities, and 28% were receiving antithrombotic therapy. The overall and complete response rates were 76% and 22.2%, respectively, with no differences according to MZL subtype, age, POD24, or MAGNOLIA trial eligibility. Fewer previous LoT were associated with higher and deeper responses. With a median follow-up of 14 months, 1-year progression-free and overall survival were 79.4% and 86.8%, respectively. Zanubrutinib responders and patients with stable disease presented better outcomes than those with progressing disease (P< .01). Adverse events (AEs) were reported in 34.1% of patients (grade ≥3 in 14.4%). MAGNOLIA trial–ineligible patients experienced a higher incidence of AEs, and bleeding events were more frequent among patients receiving anticoagulant therapy (P = .04). Overall, zanubrutinib demonstrated favorable effectiveness and safety in real-world R/R MZL, with improved outcomes when administered earlier in the disease.